CoChat

Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial

Open access
Berk, Michael, Dean, Olivia M, Cotton, Sue M, Gama, Clarissa S, Kapczinski, Flavio, Fernandes, Brisa, Kohlmann, Kristy, Jeavons, Susan, Hewitt, Karen, Moss, Kirsteen, Allwang, Christine, Schapkaitz, Ian, Cobb, Heidi, Bush, Ashley I, Dodd, Seetal, Malhi, Gin S · 2012 · BMC Medicine
Cited by 96

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: N-acetyl cysteine (NAC) is a glutathione precursor that has been shown to have antidepressant efficacy in a placebo-controlled trial. The current study aimed to investigate the maintenance effects of NAC following eight weeks of open-label treatment for bipolar disorder. METHOD: The efficacy of a double blind randomized placebo controlled trial of 2 g/day NAC as adjunct maintenance treatment for bipolar disorder was examined. Participants (n = 149) had a Montgomery Asberg Depression Rating Score of ≥12 at trial entry and, after eight weeks of open-label NAC treatment, were randomized to adjunctive NAC or placebo, in addition to treatment as usual. Participants (primarily outpatients) were recruited through public and private services and through newspaper advertisements. Time to intervention for a mood episode was the primary endpoint of the study, and changes in mood symptoms, functionality and quality of life measures were secondary outcomes. RESULTS: There was a substantial decrease in symptoms during the eight-week open-label NAC treatment phase. During the subsequent double-blind phase, there was minimal further change in outcome measures with scores remaining low. Consequently, from this low plateau, between-group differences did not emerge on recurrence, clinical functioning or quality of life measures. CONCLUSIONS: There were no significant between-group differences in recurrence or symptomatic outcomes during the maintenance phase of the trial; however, these findings may be confounded by limitations. TRIAL REGISTRATION: The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12607000074493).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1741-7015-10-91

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 28

  1. Malhi GS, Adams D, Berk M: Is lithium in a class of its own? A brief profile of its clinical use. Aust N Z J Psychiatry. 2009, 43: 1096-1104. 10.3109/00048670903279937. · DOI · Paper page
  2. Ng F, Hallam K, Lucas N, Berk M: The role of lamotrigine in the management of bipolar disorder. Neuropsychiatr Dis Treat. 2007, 3: 463-474.
  3. Malhi GS, Berk M, Bourin M, Ivanovski B, Dodd S, Lagopoulos J, Mitchell PB: A typical mood stabilizers: a "typical role for atypical antipsychotics. Acta Psychiatr Scand Suppl. 2005, 29-38. 426 · DOI
  4. Efrati S, Averbukh M, Berman S, Feldman L, Dishy V, Kachko L, Weissgarten J, Golik A, Averbukh Z: N-Acetylcysteine ameliorates lithium-induced renal failure in rats. Nephrol Dial Transplant. 2005, 20: 65-70. 10.1093/ndt/gfh573. · DOI
  5. Dean O, Bush AI, Berk M, Copolov DL, van den Buuse M: Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. Behav Brain Res. 2009, 198: 258-262. 10.1016/j.bbr.2008.11.017. · DOI · Paper page
  6. Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush AI: N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett. 2011, 499: 149-153. 10.1016/j.neulet.2011.05.027. · DOI · Paper page
  7. Dean O, Giorlando F, Berk M: N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci. 2011, 36: 78-86. · DOI · Paper page
  8. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR: Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun. 1995, 212: 375-380. 10.1006/bbrc.1995.1980. · DOI
  9. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389. 10.1192/bjp.134.4.382. · DOI · Paper page
  10. Berk M, Malhi GS, Cahill C, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M, Mitchell PB: The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord. 2007, 9: 571-579. 10.1111/j.1399-5618.2007.00536.x. · DOI
  11. Guy W: ECDEU Assessment Manual for Psychopharmacology. 1976, Rockville, MD: U.S. Department of Health
  12. Bernardo M, Dodd S, Gama CS, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI, Berk M: Effects of N-acetylcysteine on substance use in bipolar disorder: a randomized placebo controlled clinical trial. Acta Neuropsychiatrica. 2009, 21: 239-245. 10.1111/j.1601-5215.2009.00415.x. · DOI
  13. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997, 73: 159-171. 10.1016/S0165-1781(97)00123-6. · DOI · Paper page
  14. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. 1976, Washington DC: US Department of Health, Education, and Welfare, 76-338.
  15. American Psychiatric Association: DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 2000, Washington D.C.: American Psychiatric Association, 4
  16. Goldman HH, Skodol AE, Lave TR: Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992, 149: 1148-1156. · DOI · Paper page
  17. Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC: The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987, 44: 540-548. 10.1001/archpsyc.1987.01800180050009. · DOI · Paper page
  18. Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB: The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med. 1999, 29: 869-878. 10.1017/S0033291799008570. · DOI · Paper page
  19. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993, 29: 321-326.
  20. International conference on harmonisation: guidance on statistical principles for clinical trials (ICH-E9). 1997, {AU Query: Please provide the name and place of the publisher.}
  21. Mallinckrodt C, Watkin J, Molenberghs G, Carroll R: Choice of the primary analysis in longitudinal clinical trials. Pharmaceut Statist. 2004, 3: 161-169. 10.1002/pst.124. · DOI · Paper page
  22. Magalhaes PV, Dean OM, Bush AI, Copolov DL, Malhi GS, Kohlmann K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Berk M: N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord. 2011, 129: 317-320. 10.1016/j.jad.2010.08.001. · DOI · Paper page
  23. Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V: N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006, 184: 254-256. 10.1007/s00213-005-0246-6. · DOI · Paper page
  24. Grant JE, Kim SW, Odlaug BL: N-Acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007, 62: 652-657. 10.1016/j.biopsych.2006.11.021. · DOI · Paper page
  25. Qian HR, Yang Y: Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). Acta Pharmacol Sin. 2009, 30: 907-912. 10.1038/aps.2009.72. · DOI · Paper page
  26. Ferreira FR, Biojone C, Joca SR, Guimaraes FS: Antidepressant-like effects of N-acetyl-L-cysteine in rats. Behav Pharmacol. 2008, 19: 747-750. 10.1097/FBP.0b013e3283123c98. · DOI · Paper page
  27. Xiong Y, Peterson PL, Lee CP: Effect of N-acetylcysteine on mitochondrial function following traumatic brain injury in rats. J Neurotrauma. 1999, 16: 1067-1082. 10.1089/neu.1999.16.1067. · DOI · Paper page
  28. Kato T, Kapczinski F, Berk M: Mitochondrial dysfunction and oxidative stress. Bipolar Disorder: Clinical and Neurobiological Foundations. Edited by: Yatham LN, Maj M. 2010, John Wiley & Sons Ltd, London, UK, 244-254. · DOI

Cited by

See all 96

Metadata

Authors
Berk, M., Dean, O. M., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., Cobb, H., Bush, A. I., Dodd, S., & Malhi, G. S.
Venue
BMC Medicine
Published
2012-08-14
Volume
10
Issue
1
Pages
91-91
ISSN
1741-7015 (ISSN-L)
OpenAlex
W2105920925
Cited by
96
References
10
FWCI
6.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. https://app.cochat.ai/papers/10.1186/1741-7015-10-91
The paper
Berk, M., Dean, O. M., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., Cobb, H., Bush, A. I., Dodd, S., & Malhi, G. S. (2012). Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine. https://doi.org/10.1186/1741-7015-10-91

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.